What is azacitidine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

What is Azacitidine?

Azacitidine is a pyrimidine nucleoside analog and hypomethylating agent (HMA) used primarily as first-line treatment for higher-risk myelodysplastic syndromes (MDS) and certain acute myeloid leukemias (AML). 1

Drug Classification and Mechanism

Azacitidine is classified as a nucleoside metabolic inhibitor that works through two primary mechanisms 1:

  • DNA hypomethylation: Inhibits DNA methylation, restoring normal function to genes critical for cell differentiation and proliferation
  • Direct cytotoxicity: Causes death of rapidly dividing abnormal hematopoietic cells in bone marrow while sparing non-proliferating cells

The drug is a cytidine analog (4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one) with molecular weight 244.20, appearing as a white to off-white powder 1.

FDA-Approved Indications

Azacitidine is indicated for adult patients with 1:

  • Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) when accompanied by neutropenia, thrombocytopenia, or transfusion requirements
  • Refractory anemia with excess blasts (RAEB)
  • Refractory anemia with excess blasts in transformation (RAEB-T)
  • Chronic myelomonocytic leukemia (CMMoL)

Clinical Role and Evidence Base

Azacitidine represents the first-line reference treatment for most patients with higher-risk MDS 2. The ESMO 2021 guidelines provide clear treatment algorithms:

For Higher-Risk MDS Patients:

  • Patients >70 years or younger without transplant donor: Azacitidine is the recommended treatment (Level I, Grade A evidence) 2
  • Patients ≤70 years without unfavorable karyotype: Azacitidine remains first-line
  • Before stem cell transplant: 2-6 cycles commonly used to reduce blast counts 2

Key Clinical Characteristics:

Dosing regimen 2:

  • Standard: 75 mg/m² subcutaneously for 7 consecutive days every 28 days
  • Alternative: "5-2-2" regimens (often easier to apply in practice)
  • Critical point: At least 6 cycles are required, as most patients only respond after several courses

Survival benefit: Azacitidine is the only drug proven to significantly prolong survival in higher-risk MDS compared to conventional care (best supportive care, low-dose cytarabine, or intensive chemotherapy) 3.

Pharmacokinetics

After subcutaneous administration 1:

  • Bioavailability: ~89% relative to IV route
  • Peak concentration: 750 ± 403 ng/mL at 0.5 hours
  • Half-life: 41 ± 8 minutes
  • Elimination: Primarily urinary (85% of dose), with spontaneous hydrolysis and deamination (not metabolized by CYP enzymes)
  • No drug accumulation with standard dosing regimen

Important Clinical Considerations

Common Pitfalls:

  • Premature discontinuation: Responses typically occur after 3-6 cycles, not immediately 4. Hematologists must adjust expectations from traditional chemotherapy timelines
  • Elderly patients: More likely to have decreased renal function requiring monitoring 1
  • Pregnancy: Can cause fetal harm; verify pregnancy status before initiating and advise effective contraception for 6 months post-treatment in females, 3 months in males 1

Adverse Events:

  • Most common: Peripheral cytopenias 3
  • Infections: Occur in 34% of patients, particularly during first 3 cycles 5
  • Rare but notable: Seronegative inflammatory arthropathy 6, tumor lysis syndrome, sepsis 7

The drug has an acceptable tolerability profile and can be safely administered to elderly patients with comorbidities in an outpatient setting 4.

References

Related Questions

What are the side effects of azacitidine?
What are the neurological adverse effects associated with azacitidine?
How should I prepare an azacitidine infusion under aseptic conditions?
In an adult without severe hepatic impairment, respiratory disease, or a history of excessive sedation, can phenobarbital be administered once daily after a loading regimen?
In a patient with acute coronary syndrome who has active airway bleeding (bloody intubation), should a loading dose of antiplatelet and anticoagulant therapy be given?
What is the ARDSnet protocol for initiating and titrating BiPAP (bilevel positive airway pressure) in cooperative adult patients with acute respiratory distress syndrome (PaO₂/FiO₂ ratio 150–300 mmHg)?
Can oral oseltamivir be given together with intravenous ceftriaxone?
How should I manage a 43-year-old woman with three days of generalized weakness, anemia (hemoglobin 8.4 g/dL, normocytic) and a recent four‑day history of heavy menstrual bleeding?
What is the ARDSnet protocol for initiating BiPAP (bilevel positive airway pressure) in an adult patient with acute respiratory distress syndrome?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.